Oppenheimer Reiterates Outperform on Perspective Therapeutics, Adjusts Target to $19 from $2 (10-1 reverse stock split)
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on Perspective Therapeutics (AMEX:CATX) and adjusted the price target to $19 from $2 following a 10-1 reverse stock split.
June 18, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reiterated an Outperform rating on Perspective Therapeutics and adjusted the price target to $19 from $2 following a 10-1 reverse stock split.
The reiteration of an Outperform rating and a significant adjustment in the price target by a reputable analyst like Oppenheimer is likely to positively impact the stock price of Perspective Therapeutics in the short term. The 10-1 reverse stock split also indicates a strategic move to improve the stock's market perception.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100